KR20180121900A - 시티신의 숙시네이트 염 및 그의 용도 - Google Patents

시티신의 숙시네이트 염 및 그의 용도 Download PDF

Info

Publication number
KR20180121900A
KR20180121900A KR1020187025475A KR20187025475A KR20180121900A KR 20180121900 A KR20180121900 A KR 20180121900A KR 1020187025475 A KR1020187025475 A KR 1020187025475A KR 20187025475 A KR20187025475 A KR 20187025475A KR 20180121900 A KR20180121900 A KR 20180121900A
Authority
KR
South Korea
Prior art keywords
salt
citric acid
pharmaceutical composition
cytosine
lactose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020187025475A
Other languages
English (en)
Korean (ko)
Inventor
앤서니 클라크
리차드 알리스터 스튜어트
앤드류 가렛 윌리스
Original Assignee
어치브 파마 유케이 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 어치브 파마 유케이 리미티드 filed Critical 어치브 파마 유케이 리미티드
Priority to KR1020257017169A priority Critical patent/KR20250078632A/ko
Priority to KR1020247009722A priority patent/KR20240042257A/ko
Priority to KR1020247042937A priority patent/KR20250004182A/ko
Publication of KR20180121900A publication Critical patent/KR20180121900A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020187025475A 2016-02-05 2017-02-06 시티신의 숙시네이트 염 및 그의 용도 Ceased KR20180121900A (ko)

Priority Applications (3)

Application Number Priority Date Filing Date Title
KR1020257017169A KR20250078632A (ko) 2016-02-05 2017-02-06 시티신의 숙시네이트 염 및 그의 용도
KR1020247009722A KR20240042257A (ko) 2016-02-05 2017-02-06 시티신의 숙시네이트 염 및 그의 용도
KR1020247042937A KR20250004182A (ko) 2016-02-05 2017-02-06 시티신의 숙시네이트 염 및 그의 용도

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1602145.3A GB201602145D0 (en) 2016-02-05 2016-02-05 Salt
GB1602145.3 2016-02-05
PCT/GB2017/050294 WO2017134468A1 (en) 2016-02-05 2017-02-06 Succinate salt of cytisine and use thereof

Related Child Applications (3)

Application Number Title Priority Date Filing Date
KR1020257017169A Division KR20250078632A (ko) 2016-02-05 2017-02-06 시티신의 숙시네이트 염 및 그의 용도
KR1020247042937A Division KR20250004182A (ko) 2016-02-05 2017-02-06 시티신의 숙시네이트 염 및 그의 용도
KR1020247009722A Division KR20240042257A (ko) 2016-02-05 2017-02-06 시티신의 숙시네이트 염 및 그의 용도

Publications (1)

Publication Number Publication Date
KR20180121900A true KR20180121900A (ko) 2018-11-09

Family

ID=55641904

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020187025475A Ceased KR20180121900A (ko) 2016-02-05 2017-02-06 시티신의 숙시네이트 염 및 그의 용도
KR1020247009722A Ceased KR20240042257A (ko) 2016-02-05 2017-02-06 시티신의 숙시네이트 염 및 그의 용도
KR1020247042937A Pending KR20250004182A (ko) 2016-02-05 2017-02-06 시티신의 숙시네이트 염 및 그의 용도
KR1020257017169A Pending KR20250078632A (ko) 2016-02-05 2017-02-06 시티신의 숙시네이트 염 및 그의 용도

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020247009722A Ceased KR20240042257A (ko) 2016-02-05 2017-02-06 시티신의 숙시네이트 염 및 그의 용도
KR1020247042937A Pending KR20250004182A (ko) 2016-02-05 2017-02-06 시티신의 숙시네이트 염 및 그의 용도
KR1020257017169A Pending KR20250078632A (ko) 2016-02-05 2017-02-06 시티신의 숙시네이트 염 및 그의 용도

Country Status (17)

Country Link
US (1) US10300050B2 (enExample)
EP (2) EP4265298A3 (enExample)
JP (4) JP6820344B2 (enExample)
KR (4) KR20180121900A (enExample)
CN (1) CN108883101A (enExample)
AU (2) AU2017215300B2 (enExample)
CA (1) CA3013454C (enExample)
DK (1) DK3411029T3 (enExample)
ES (1) ES2963451T3 (enExample)
GB (2) GB201602145D0 (enExample)
MX (1) MX372607B (enExample)
PL (1) PL3411029T3 (enExample)
PT (1) PT3411029T (enExample)
SI (1) SI3411029T1 (enExample)
SM (1) SMT202300416T1 (enExample)
WO (1) WO2017134468A1 (enExample)
ZA (1) ZA201805296B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201602145D0 (en) * 2016-02-05 2016-03-23 Achieve Pharma Uk Ltd Salt
KR102848174B1 (ko) * 2017-07-24 2025-08-27 어치브 파마 유케이 리미티드 시티신 염
EP3598968A1 (en) * 2018-07-23 2020-01-29 Adamed Pharma S.A. Solid pharmaceutical cytisine composition
CN119564619A (zh) * 2019-09-12 2025-03-07 阿奇维生命科学公司 治疗和/或预防有需要的受试者的成瘾的包括野靛碱的组合物
CN116509857A (zh) * 2023-04-11 2023-08-01 广州医科大学 金雀花碱的新应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698224A (en) 1994-06-27 1997-12-16 Alza Corporation Tacrine therapy
AU5091896A (en) 1995-03-06 1996-09-23 Lectec Corporation Nicotine-free smoking material
EP0937077B1 (en) 1996-10-30 2006-05-17 Pfizer Inc. Pyridone-fused azabicyclic- or cytisine derivatives, their preparation and their use in addiction therapy
RU2228179C2 (ru) 2002-07-22 2004-05-10 Институт органической химии Уфимского научного центра РАН Гидрохлорид n-(бета-гидроксиэтил)цитизина, проявляющий антиаритмическую активность
WO2004103284A2 (en) 2003-05-14 2004-12-02 Pharmacia Corporation Compositions of a benzenesulfonamide or methylsulfonylbenzene cyclooxygenase-2 selective inhibitor and a cholinergic agent for the treatment of reduced blood flow or trauma to the central nervous system
BG65536B1 (bg) 2004-04-16 2008-11-28 "Софарма" Ад Лекарствена форма, съдържаща цитизин
WO2007115092A2 (en) * 2006-03-29 2007-10-11 Georgetown University 10-substituted cytisine derivatives and methods of use thereof
CN101428021B (zh) * 2007-11-09 2012-07-18 江苏中康药物科技有限公司 一种用于戒除烟瘾酒瘾的外用药物制剂
WO2011133858A2 (en) 2010-04-23 2011-10-27 University Of Florida Research Foundation, Inc. Compositions, methods of use, and methods of treatment
CN102167680B (zh) 2011-03-23 2014-07-02 合亚医药科技（上海）有限公司 八氢环戊基并[c]吡咯羧酸衍生物的制备方法
WO2012172368A1 (en) * 2011-06-17 2012-12-20 Astrazeneca Ab Process for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof
CN103044423B (zh) 2012-01-11 2013-10-23 上海合全药物研发有限公司 取代的吡啶-2-酮类化合物及其制备方法
CN103509021B (zh) 2012-06-21 2016-08-17 天津药明康德新药开发有限公司 金雀花碱衍生物及其制备方法和抗癌作用研究
FR2992315B1 (fr) 2012-06-25 2014-08-08 Pf Medicament Derives utiles dans le traitement de maladies du systeme nerveux central
US20170209415A1 (en) 2012-08-13 2017-07-27 Anthony Alexander McKINNEY Use of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane to treat addictive disorders including nicotine addiction
PL220354B1 (pl) 2012-11-19 2015-10-30 Aflofarm Fabryka Leków Spółka Z Ograniczoną Odpowiedzialnością Stała postać dawkowania zawierająca zmikronizowaną cytyzynę oraz sposób jej otrzymywania
CN102952134B (zh) 2012-12-05 2015-01-07 苏州药明康德检测检验有限责任公司 含二氟甲基的金雀花碱衍生物及制备方法和抗癌作用研究
CN103284319A (zh) 2013-06-20 2013-09-11 昌宁德康生物科技有限公司 一种金雀花碱替代尼古丁口腔雾化液及其制备方法
GB201315030D0 (en) * 2013-08-22 2013-10-02 Knight Martin Magazine
WO2015025718A1 (ja) * 2013-08-23 2015-02-26 久光製薬株式会社 貼付剤
CN103588773B (zh) 2013-11-07 2016-01-06 东南大学 一种金雀花碱的提取分离方法
CN104710422A (zh) * 2013-12-13 2015-06-17 上海壹志医药科技有限公司 金雀花碱衍生物
PL408608A1 (pl) * 2014-06-18 2015-12-21 Pharmacia Polonica Spółka Z Ograniczoną Odpowiedzialnością Trwała stała kompozycja farmaceutyczna cytyzyny oraz sposób jej wytwarzania
PL409830A1 (pl) 2014-10-18 2016-04-25 Łukasz Zalewski Papieros z cytyzyną
GB201602145D0 (en) 2016-02-05 2016-03-23 Achieve Pharma Uk Ltd Salt
CN106188057A (zh) 2016-07-21 2016-12-07 西安岳达生物科技股份有限公司 一种金雀花碱的分离提取方法
AU2017313390A1 (en) 2016-08-19 2019-03-07 The University Of Bristol Cytisine derivatives for the treatment of addiction

Also Published As

Publication number Publication date
JP2019504848A (ja) 2019-02-21
AU2017215300B2 (en) 2022-03-03
KR20250004182A (ko) 2025-01-07
AU2022203808A1 (en) 2022-06-23
ZA201805296B (en) 2019-04-24
JP2021073197A (ja) 2021-05-13
JP6820344B2 (ja) 2021-01-27
SI3411029T1 (sl) 2024-04-30
MX372607B (es) 2020-04-30
JP2025038099A (ja) 2025-03-18
KR20240042257A (ko) 2024-04-01
AU2022203808B2 (en) 2023-10-19
JP2023113803A (ja) 2023-08-16
ES2963451T3 (es) 2024-03-27
GB2550241A (en) 2017-11-15
EP3411029B1 (en) 2023-11-01
MX2018009364A (es) 2019-05-15
SMT202300416T1 (it) 2024-01-10
PL3411029T3 (pl) 2024-01-29
CN108883101A (zh) 2018-11-23
EP4265298A2 (en) 2023-10-25
KR20250078632A (ko) 2025-06-02
NZ744953A (en) 2024-11-29
PT3411029T (pt) 2023-11-30
WO2017134468A1 (en) 2017-08-10
EP4265298A3 (en) 2024-01-10
CA3013454A1 (en) 2017-08-10
JP7292316B2 (ja) 2023-06-16
GB2550241B (en) 2018-04-25
US10300050B2 (en) 2019-05-28
GB201602145D0 (en) 2016-03-23
US20190038608A1 (en) 2019-02-07
CA3013454C (en) 2020-02-25
GB201701939D0 (en) 2017-03-22
AU2017215300A1 (en) 2018-08-23
EP3411029A1 (en) 2018-12-12
DK3411029T3 (da) 2023-11-27

Similar Documents

Publication Publication Date Title
JP7292316B2 (ja) シチシンのコハク酸塩およびその使用
EP1818057B1 (en) Stable pharmaceutical formulations of montelukast sodium
US20150133463A1 (en) Multicomponent crystals comprising dasatinib and selected co-crystal formers
US20220380369A1 (en) Cytisine salts
JP7212958B2 (ja) バルベナジントシル酸塩の結晶形及びその製造方法並びに用途
US20150150819A1 (en) Compositions containing opioid antagonists
US12492209B2 (en) Substituted [1,2,4]triazolo[4,3-c]pyrimidines that induce degradation of embryonic ectoderm development (EED) protein
US12491252B2 (en) Substituted 3-amino-5-phenylbenzamide compounds as covalent inhibitors of enhancer zeste homolog 2 (EZH2) and proteolysis-targeting chimeric derivatives thereof (PROTACs) that induce degradation of EZH2
HK40093180A (en) Salt
US20160376245A1 (en) Impurity of famotidine
US20060094771A1 (en) Carvedilol pharmasolve solvate

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20180903

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220117

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240122

Patent event code: PE09021S01D

PE0601 Decision on rejection of patent

Patent event date: 20240924

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20241226

E601 Decision to refuse application
E801 Decision on dismissal of amendment
PE0601 Decision on rejection of patent

Patent event date: 20250221

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

PE0801 Dismissal of amendment

Patent event code: PE08012E01D

Comment text: Decision on Dismissal of Amendment

Patent event date: 20250221